Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza. Issue 4 (April 2020)

• Record Type: Journal Article
• Authors: Van Poelvoorde, Laura A.E.; Saelens, Xavier; Thomas, Isabelle; Roosens, Nancy H.
• Is Part Of: Trends in biotechnology. Volume 38:Issue 4(2020)
• Page Start: 360
• Page End: 367
• Publication Date: 2020-04
• Subjects: next-generation sequencing -- influenza -- antiviral resistance -- surveillance; Biotechnology -- Periodicals; Biochemical engineering -- Periodicals; Genetic engineering -- Periodicals; Industrial microbiology -- Periodicals; 660.605
• DOI: 10.1016/j.tibtech.2019.09.009
• Languages: English
• ISSNs: 0167-7799

Abstract

Abstract : Next-generation sequencing (NGS) can enable a more effective response to a wide range of communicable disease threats, such as influenza, which is one of the leading causes of human morbidity and mortality worldwide. After vaccination, antivirals are the second line of defense against influenza. The use of currently available antivirals can lead to antiviral resistance mutations in the entire influenza genome. Therefore, the methods to detect these mutations should be developed and implemented. In this Opinion, we assess how NGS could be implemented to detect drug resistance mutations in clinical influenza virus isolates. Highlights: Sanger sequencing remains sufficient when only a few samples are analyzed and only the NA gene is sequenced. With the development of new antivirals that also target other proteins than the NA protein, resistance mutations could arise across the whole genome. In this case, sequencing only the NA segment will not be sufficient anymore and NGS will be the better option. NGS opens the possibility to analyze the minority variants present in the sample. This could give the possibility to detect the emergence of antiviral resistance at an early stage.